| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| Targets |
Plasmodium; Bcl-2; Bax; Caspase-7; Caspase-8; PARP
|
|---|---|
| ln Vitro |
Treatment with dehydrocorydaline (0-200 μM) markedly and dose-dependently reduced the proliferation of MCF-7 cells. Cell viability was almost 40% lower after a 24-hour treatment with 200 μM DeHydrocorydaline[1]. DeHydrocorydaline (0 - 200 μM) activates the PARP pathway, caspase-7, and -8, and causes a dose-dependent reaction without impacting caspase-9[1].
|
| ln Vivo |
The acute toxicity of dehydrocordine is minimal. The LD50 for intraperitoneal injection is approximately 21.1±1.4 mg/kg, while for mice, it is approximately 277.5±19.0 mg/kg body weight[4].
|
| References |
[1]. Xu Z, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85.
[2]. Yoo M, et al. Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016 Oct;14(4):3029-36. [3]. Nonaka M, et al. Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts. Malar J. 2018 Jun 25;17(1):244. [4]. Yin ZY, et al. Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep. 2016 Jun 7;6:27129. |
| Additional Infomation |
Dehydrocorydaline is an alkaloid.
Dehydrocorydaline has been reported in Corydalis solida, Corydalis yanhusuo, and other organisms with data available. |
| Molecular Formula |
C22H24NO4+
|
|---|---|
| Molecular Weight |
366.4303
|
| Exact Mass |
366.171
|
| CAS # |
30045-16-0
|
| Related CAS # |
Dehydrocorydaline chloride;10605-03-5;Dehydrocorydaline (hydroxyl);Dehydrocorydaline nitrate;13005-09-9
|
| PubChem CID |
34781
|
| Appearance |
Solid
|
| Melting Point |
170-173℃
|
| LogP |
3.693
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
503
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1=C(C([H])=C([H])C2C1=C([H])[N+]1C([H])([H])C([H])([H])C3=C([H])C(=C(C([H])=C3C=1C=2C([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H]
|
| InChi Key |
RFKQJTRWODZPHF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H24NO4/c1-13-15-6-7-18(24-2)22(27-5)17(15)12-23-9-8-14-10-19(25-3)20(26-4)11-16(14)21(13)23/h6-7,10-12H,8-9H2,1-5H3/q+1
|
| Chemical Name |
2,3,9,10-tetramethoxy-13-methyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium
|
| Synonyms |
Dehydrocorydaline; 13-Methylpalmatine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50~73 mg/mL (136.5~199.2 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (17.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 6.25 mg/mL (17.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7290 mL | 13.6452 mL | 27.2903 mL | |
| 5 mM | 0.5458 mL | 2.7290 mL | 5.4581 mL | |
| 10 mM | 0.2729 mL | 1.3645 mL | 2.7290 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
